Drug Price Trends for PENTOXIFYLLINE ER

Average Pharmacy Cost for PENTOXIFYLLINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
PENTOXIFYLLINE ER 400 MG TAB	60505-0033-06	0.28815	EACH	2025-03-19
PENTOXIFYLLINE ER 400 MG TAB	60505-0033-07	0.28815	EACH	2025-03-19
PENTOXIFYLLINE ER 400 MG TAB	16571-0856-50	0.28815	EACH	2025-03-19
PENTOXIFYLLINE ER 400 MG TAB	70954-0668-10	0.28815	EACH	2025-03-19
PENTOXIFYLLINE ER 400 MG TAB	00904-5448-61	0.28815	EACH	2025-03-19
PENTOXIFYLLINE ER 400 MG TAB	70954-0668-20	0.28815	EACH	2025-03-19

Market Analysis and Price Projections for Pentoxifylline ER

Introduction to Pentoxifylline ER

Pentoxifylline, a member of the miscellaneous coagulation modifiers drug class, is commonly used to treat intermittent claudication, a condition characterized by leg pain during walking. The extended-release (ER) formulation of pentoxifylline is designed to provide sustained release of the medication, enhancing patient compliance and therapeutic efficacy.

Current Market Size and Revenue

The current annual U.S. market for Pentoxifylline ER Tablets is estimated to be approximately $19.7 million, according to data from IQVIA/IMS Health[5].

Pricing Trends

Retail Prices

For cash-paying customers, the cost of pentoxifylline 400 mg oral tablets, extended release, can vary depending on the pharmacy. On average, a supply of 100 tablets can cost around $38, with prices ranging from $0.38 to $0.30 per unit for larger quantities[2].

Historical Price Data

Historical price data indicates fluctuations in the unit price of pentoxifylline ER 400 mg tablets. For example, prices per unit have ranged from $0.26913 to $0.34482 over the past year, reflecting market dynamics and supply chain variations[1].

Market Growth Projections

Forecast Period

The pentoxifylline drug market is expected to experience significant growth from 2024 to 2031. This growth is driven by increasing demand for treatments of intermittent claudication and other vascular diseases. The market is projected to expand at a remarkable Compound Annual Growth Rate (CAGR) during this period[3].

Market Segmentation

The market is segmented by type (tablets and injections) and application (hospitals and medical centers), with geographical regions including North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. This segmentation helps in understanding the diverse market dynamics and growth opportunities across different regions and sectors[3].

Key Drivers and Restraints

Drivers

• Increasing Prevalence of Vascular Diseases: The rising incidence of intermittent claudication and other vascular conditions is a significant driver for the pentoxifylline market.
• Advancements in Healthcare Infrastructure: Improvements in healthcare facilities, especially in developing regions, are expected to boost the demand for pentoxifylline.
• Generic Market Expansion: The launch of generic versions, such as ANI Pharmaceuticals' recent launch, increases market competition and accessibility[5].

Restraints

• Regulatory Challenges: Changes in FDA policies and regulatory actions can impact the market negatively.
• Supply Chain Issues: Manufacturing and supply chain disruptions can affect product availability and pricing.
• Economic Factors: Economic conditions, including inflation and geopolitical tensions, can influence market growth[5].

Competitive Landscape

The pentoxifylline market is competitive, with several key players involved in the production and distribution of the drug. Companies such as Infa Group spa, Polpharma S.A., Bakul Group, Saneca Pharmaceuticals, and ANI Pharmaceuticals are prominent in this market. The entry of generic versions, like ANI Pharmaceuticals' Pentoxifylline ER Tablets, USP 400mg, further intensifies the competition[3][5].

Patient Assistance and Copay Programs

While there are no specific patient assistance programs (PAPs) or copay programs available for pentoxifylline, patients can benefit from discount cards and other savings programs. For instance, the Drugs.com Discount Card can save patients up to 80% on prescription medications, including pentoxifylline[2].

Economic Impact

The pentoxifylline market is influenced by broader economic and geopolitical factors. The ongoing impact of the COVID-19 pandemic and inflationary pressures, as well as geopolitical conflicts, can affect the pricing and availability of the drug. A thorough analysis of the macroeconomic environment is crucial for understanding the market's future trajectory[4].

Market Dynamics and Opportunities

Market News and Developments

Recent launches, such as ANI Pharmaceuticals' introduction of Pentoxifylline ER Tablets, highlight the dynamic nature of the market. These developments indicate a growing interest in generic and affordable treatments for vascular diseases[5].

Challenges and Opportunities

Despite the growth potential, the market faces challenges such as regulatory hurdles, supply chain disruptions, and economic uncertainties. However, these challenges also present opportunities for innovation and strategic market entry. Companies can leverage market research and feasibility studies to identify new project opportunities and develop effective market entry strategies[4].

Conclusion

The pentoxifylline ER market is poised for significant growth driven by increasing demand for vascular disease treatments and the expansion of generic market offerings. Understanding the current pricing trends, market segmentation, and competitive landscape is crucial for stakeholders to navigate this market effectively.

Key Takeaways

• The U.S. market for Pentoxifylline ER Tablets is valued at approximately $19.7 million annually.
• The market is expected to grow at a remarkable CAGR from 2024 to 2031.
• Pricing varies, with an average cost of $38 for 100 tablets for cash-paying customers.
• Key drivers include the increasing prevalence of vascular diseases and advancements in healthcare infrastructure.
• Regulatory challenges, supply chain issues, and economic factors are significant restraints.
• The competitive landscape is marked by the presence of several key players and the entry of generic versions.

FAQs

What is the current annual U.S. market size for Pentoxifylline ER Tablets?

The current annual U.S. market for Pentoxifylline ER Tablets is approximately $19.7 million[5].

How much does a supply of 100 Pentoxifylline ER 400 mg tablets typically cost?

A supply of 100 tablets can cost around $38, with prices ranging from $0.38 to $0.30 per unit for larger quantities[2].

What are the key drivers of the pentoxifylline market growth?

Key drivers include the increasing prevalence of vascular diseases and advancements in healthcare infrastructure[3].

Are there any patient assistance programs available for Pentoxifylline?

There are no specific patient assistance programs (PAPs) or copay programs available for pentoxifylline, but patients can use discount cards for savings[2].

Who are the key players in the pentoxifylline market?

Key players include Infa Group spa, Polpharma S.A., Bakul Group, Saneca Pharmaceuticals, and ANI Pharmaceuticals[3].

Sources

1. Drug Patent Watch: Latest pharmaceutical drug prices and trends for NDC 00904-5448.
2. Drugs.com: Pentoxifylline Prices, Coupons, Copay Cards & Patient Assistance.
3. Market Research Intellect: Global Pentoxifylline Drug Market Size, Trends and Projections.
4. Prof-Research: Pentoxifylline Market Size, Share, Trend and Forecast to 2025.
5. ANI Pharmaceuticals: ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP.